Adverum Biotechnologies, Inc. (ADVM)

11.35 -0.26 (-2.24%) 收市：04:00PM EDT

Adverum Biotechnologies, Inc.

100 Cardinal Way
Redwood City, CA 94063
United States
650 656 9323
https://adverum.com

版塊: Healthcare
行業: Biotechnology
全職員工: 121

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Laurent Fischer	President, CEO & Director	1.02M	無	1964
Ms. Linda M. Rubinstein M.A.	CFO, Principal Financial Officer & Principal Accounting Officer	940.99k	無	1967
Mr. Kishor Peter Soparkar J.D.	Chief Operating Officer	674.98k	無	1972
Dr. Setareh Seyedkazemi Pharm.D.	Chief Development Officer	656.84k	無	1975
Dr. R. Andrew Ramelmeier Ph.D.	Chief Technology Officer	無	無	1962
Dr. Romuald Corbau Ph.D.	Chief Scientific Officer	無	無	1969
Mr. John W. Rakow J.D.	Senior VP & General Counsel	954.24k	無	1957
Ms. Dena House	Chief People Officer	無	無	無
Ms. Carla Fiankan	Senior Vice President of Regulatory Affairs	無	無	無
Mr. Michael Steel	Senior Vice President of Quality	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

公司管治

截至 2024年4月1日 止，Adverum Biotechnologies, Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：6；董事會：5；股東權利：8；現金賠償：9。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。